Additionally, if longitudinal proteomic data from within subjects becomes available, re-running these analyses as repeated measures within subjects would allow us to better determine if RGS10 levels change with PD progression, advanced age, and/or years with disease. This evidence concerns the gene RGS10 and Parkinson disease.